The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Can a galacto-oligosaccharide reduce the risk of traveller’s diarrhoea? A placebo-controlled, randomized, double-blind study
Abstract
BACKGROUND: Diarrhoea is a common medical problem affecting travellers to Asia, Africa and Latin America. The use of prophylactic antimicrobial agents may increase the risk of contracting resistant bacteria. Findings indicate that oligosaccharides, i.e. carbohydrate chains of 3-10 monosaccharides, reduce the risk of diarrhoea. METHODS: We performed a placebo-controlled, double-blind study of a galacto-oligosaccharide, B-GOS (Bimuno®, Clasado Ltd, Milton Keynes UK), vs placebo for participants travelling to countries with a high/intermediate risk of diarrhoea for 7-15 days. The participants ingested 2.7g of B-GOS daily from 5 days prior to departure throughout the travel period, and returned a questionnaire, with a diarrhoea log, after their return. The case definition of diarrhoea was three or more loose stools per day. RESULTS: Of 523 enrolled subjects, 334 travellers managed to comply per protocol (PP), 349 followed the protocol at least until the onset of diarrhoea (conditionally evaluable, CE), and 408 followed the protocol with fewer than 5 days of deviance from the protocol (intention to treat, ITT). There was a significant reduction of diarrhoea incidence in the PP group (odds ratio = 0.56, P = 0.03), while the effect in the CE group was non-significant (OR = 0.65, P = 0.08). No significant effect was found during the first 7 days after starting with B-GOS, but from day 8 there was a significant effect in both the PP and CE groups (OR = 0.47, P = 0.02 and OR = 0.53, P = 0.03, respectively). The entire effect was seen in 1-day (i.e. self-limiting) diarrhoea (PP: OR = 0.25, P = 0.004). There was no effect on duration or the number of bowel movements during diarrhoea. The severity of diarrhoea was not affected. CONCLUSIONS: B-GOS reduces the risk of diarrhoea lasting 1 day. The protection seemed to start after a week of treatment with B-GOS. Strict compliance is crucial. The treatment is environmentally friendly and without adverse effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a 12-week randomized placebo-controlled trial, overweight adults (BMI 25-35) receiving L. gasseri BNR17 (10 billion CFU/day) had a ~22 cm 2 decrease in visceral adiposity and reduced waist circumference versus placebo”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [143]
In the citing paper
“Thus, specific probiotics may support endogenous GLP-1 signaling and potentially complement GLP-1RAs by visceral fat, body weight, and waist circumference reduction [143,144,257]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [143]
In the citing paper
“Another trial observed reduced BMI and waist and hip circumferences compared to baseline in individuals with BMI ≥ 23 kg/m 2 , even with no change in diet or behavior [143].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [143]
In the citing paper
“Another trial observed reduced BMI and waist and hip circumferences compared to baseline in individuals with BMI ≥ 23 kg/m 2 , even with no change in diet or behavior [143].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [143]
In the citing paper
“Another trial observed reduced BMI and waist and hip circumferences compared to baseline in individuals with BMI ≥ 23 kg/m 2 , even with no change in diet or behavior [143].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [143]
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics
Gibson, G. R., & Roberfroid, M. B. (1995) · The Journal of Nutrition · doi:10.1093/jn/125.6.1401 · Cited by 7,667
Non-digestible oligosaccharides: A review
Mussatto, S. I., & Mancilha, I. M. (2007) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2006.12.011 · Cited by 819
Advances in Food and Nutrition Research
Taylor, S. (2003) · Medical Entomology and Zoology · Cited by 760
Sazawal, S., Hiremath, G., Dhingra, U., Malik, P., Deb, S., & Black, R. E. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70495-9 · Cited by 561
Galdeano, C. M., & Perdigón, G. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.13.2.219-226.2006 · Cited by 535
Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants
Morrow, A. L., Ruiz-Palacios, G. M., Altaye, M., Jiang, X., Lourdes Guerrero, M., Meinzen-Derr, J. K., Farkas, T., Chaturvedi, P., Pickering, L. K., & Newburg, D. S. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.04.054 · Cited by 464
Arcilla, M. S., van Hattem, J. M., Haverkate, M. R., Bootsma, M. C. J., van Genderen, P. J. J., Goorhuis, A., Grobusch, M. P., Lashof, A. M. O., Molhoek, N., Schultsz, C., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30319-x · Cited by 462
Vulevic, J., Drakoularakou, A., Yaqoob, P., Tzortzis, G., & Gibson, G. R. (2008) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26242 · Cited by 451 · cited 6×
“It is unlikely that a single prophylactic measure can offer 100% effective protection against TD.”
BackgroundInfluentialTraveler’s Diarrhea: A Clinical Review
Steffen, R., Hill, D. R., & DuPont, H. L. (2015) · JAMA · doi:10.1001/jama.2014.17006 · Cited by 349
Research works printed but not linked: 3
- 2000, Principels and Practice of Infectious Diseases, 2276
- 2000, Principels and Practice of Infectious Diseases, 2344
- 2000, Principels and Practice of Infectious Diseases, 2363
Cited by
Bae, J.-M. (2018) · Epidemiology and Health · doi:10.4178/epih.e2018043 · Cited by 37
Parker, C., Hunter, K. A., Johnson, M. A., Sharpe, G. R., Gibson, G. R., Walton, G. E., Poveda, C., Cousins, B., & Williams, N. C. (2023) · European Journal of Sport Science · doi:10.1080/17461391.2023.2216657 · Cited by 13
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025) · Obesities · doi:10.3390/obesities5040088 · Cited by 8
Metadata
- Authors
- Hasle, G., Raastad, R., Bjune, G., Jenum, P. A., & Heier, L.
- Affiliations
- University of Oslo (NO)
- Corresponding author
- Hasle, Gunnar
- Venue
- Journal of Travel Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-18
- Volume
- 24
- Issue
- 5
- ISSN
- 1195-1982 (ISSN-L)
- 1708-8305
- OpenAlex
- W2758055522
- Cited by
- 28
- References
- 32
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 5 · 2018: 4 · 2017: 2
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Travel Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
- Health Sciences › Nursing › Nutrition and Dietetics › Microbial Metabolites in Food Biotechnology
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- galactooligosaccharides, traveler's diarrhea, prebiotics, diarrhea prevention, antimicrobial resistance, dietary supplementation, travel medicine, medication adherence, duration of protection, diarrhea severity
- MeSH terms
- Adult, Anti-Infective Agents, Diarrhea, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Oligosaccharides, Surveys and Questionnaires, Travel, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can a galacto-oligosaccharide reduce the risk of traveller’s diarrhoea? A placebo-controlled, randomized, double-blind study. https://app.cochat.ai/papers/10.1093/jtm/tax057
- The paper
- Hasle, G., Raastad, R., Bjune, G., Jenum, P. A., & Heier, L. (2017). Can a galacto-oligosaccharide reduce the risk of traveller’s diarrhoea? A placebo-controlled, randomized, double-blind study. Journal of Travel Medicine. https://doi.org/10.1093/jtm/tax057
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.